Who is sponsoring NCT02554786?

NCT02554786 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT02554786?

Interventions in NCT02554786: Indacaterol acetate/Mometasone furoate, Mometasone furoate, Salmeterol xinafoate/fluticasone propionate.

Is NCT02554786 still recruiting?

NCT02554786 is currently completed. Last updated 5 March 2020.

Are results published for NCT02554786?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-03-05 · How we verify

NCT02554786

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma

Completed Phase 3 Results posted Last updated 5 March 2020

What this trial tests

Phase 3 trial testing Indacaterol acetate/Mometasone furoate in Asthma in 2,216 participants. Completed in 28 June 2019.

Timeline

29 December 2015

Primary endpoint
21 November 2018

28 June 2019

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	2,216
Start date	29 December 2015
Primary completion	21 November 2018
Estimated completion	28 June 2019
Sites	388 locations across Japan, Ireland, Poland, South Korea, Guatemala, Croatia, Russia, Estonia

Drugs / interventions tested

Indacaterol acetate/Mometasone furoate
Mometasone furoate (MOMETASONE FUROATE) — full drug profile →
Salmeterol xinafoate/fluticasone propionate

Conditions studied

Asthma — all drugs for Asthma →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

Adults 12 to 75, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26 Primary · 26 weeks

Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.

Group	Value	95% CI
QMF149 150/320 μg	2.383	± 0.0159
QMF149 150/160 μg	2.387	± 0.0160
MF 800 μg	2.250	± 0.0162
MF 400 μg	2.176	± 0.0162
Salmeterol/Fluticasone 50/500 μg	2.346	± 0.0160

Asthma Control Questionnaire (ACQ-7) at Weeks 4, 12, 26 and 52 Secondary · Weeks 4, 12, 26 and 52

The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway calibre (FEV1 % predicted). All 7 questions of the ACQ-7 were equally weighted. Items 1-5 were scored along a 7-point response scale, where 0 = totally controlled and 6 = severely uncontrolled. Item 6 is scored between 0 = no rescue medication and 6 = More than 16 puffs/inhalations most days. The 7th item was scored by the investigator based on the FEV1 % predicted from the masterscope at the site (i.e., Score = 0 means \> 95% of predicted FEV1, 1 = 90 - 95

Week 4

Group	Value	95% CI
QMF149 150/320 μg	1.486	± 0.0337
QMF149 150/160 μg	1.533	± 0.0338
MF 800 μg	1.659	± 0.0338
MF 400 μg	1.730	± 0.0337
Salmeterol/Fluticasone 50/500 μg	1.541	± 0.0335

Week 12

Group	Value	95% CI
QMF149 150/320 μg	1.394	± 0.0347
QMF149 150/160 μg	1.377	± 0.0348
MF 800 μg	1.523	± 0.0348
MF 400 μg	1.625	± 0.0350
Salmeterol/Fluticasone 50/500 μg	1.445	± 0.0345

Week 26

Group	Value	95% CI
QMF149 150/320 μg	1.267	± 0.0350
QMF149 150/160 μg	1.261	± 0.0350
MF 800 μg	1.439	± 0.0352
MF 400 μg	1.509	± 0.0354
Salmeterol/Fluticasone 50/500 μg	1.322	± 0.0349

Week 52

Group	Value	95% CI
QMF149 150/320 μg	1.231	± 0.0358
QMF149 150/160 μg	1.183	± 0.0356
MF 800 μg	1.373	± 0.0359
MF 400 μg	1.449	± 0.0361
Salmeterol/Fluticasone 50/500 μg	1.221	± 0.0354

Trough FEV1 at Week 52 Secondary · Week 52

Group	Value	95% CI
QMF149 150/320 μg	2.386	± 0.0168
QMF149 150/160 μg	2.357	± 0.0167
MF 800 μg	2.249	± 0.0170
MF 400 μg	2.148	± 0.0170
Salmeterol/Fluticasone 50/500 μg	2.338	± 0.0167

Pre-dose FEV1 at Weeks 4 and 12 Secondary · Weeks 4 (Day 30) and 12 (Day 86)

Pre-dose trough FEV1 is defined as average of the two FEV1 measurements taken 45 min and 15 min pre evening dose. It was assessed by performing spirometric assessment. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.

Day 30

Group	Value	95% CI
QMF149 150/320 μg	2.369	± 0.0141
QMF149 150/160 μg	2.367	± 0.0142
MF 800 μg	2.237	± 0.0143
MF 400 μg	2.171	± 0.0143
Salmeterol /Fluticasone 50/500 μg	0.2333	± 0.0141

Day 86

Group	Value	95% CI
QMF149 150/320 μg	2.368	± 0.0148
QMF149 150/160 μg	2.361	± 0.0148
MF 800 μg	2.245	± 0.0148
MF 400 μg	2.177	± 0.0149
Salmeterol /Fluticasone 50/500 μg	2.330	± 0.0146

Post Dose FEV1 (5 Minutes-1 Hour) Secondary · Up to Week 52 (Day 364)

Post-dose FEV1 measurements were analyzed at 5 minutes, 15 minutes, 30 minutes and 1 hour. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.

Day 1: 5 minutes

Group	Value	95% CI
QMF149 150/320 μg	2.279	± 0.0084
QMF149 150/160 μg	2.270	± 0.0085
MF 800 μg	2.138	± 0.0085
MF 400 μg	2.118	± 0.0084
Salmeterol/Fluticasone 50/500 μg	2.224	± 0.0084

Day 1: 15 minutes

Group	Value	95% CI
QMF149 150/320 μg	2.321	± 0.0088
QMF149 150/160 μg	2.312	± 0.0089
MF 800 μg	2.159	± 0.0089
MF 400 μg	2.137	± 0.0089
Salmeterol/Fluticasone 50/500 μg	2.278	± 0.0088

Day 1: 30 minutes

Group	Value	95% CI
QMF149 150/320 μg	2.338	± 0.0095
QMF149 150/160 μg	2.326	± 0.0096
MF 800 μg	2.162	± 0.0096
MF 400 μg	2.141	± 0.0095
Salmeterol/Fluticasone 50/500 μg	2.310	± 0.0095

Day 1: 1 hour

Group	Value	95% CI
QMF149 150/320 μg	2.343	± 0.0100
QMF149 150/160 μg	2.347	± 0.0101
MF 800 μg	2.166	± 0.0101
MF 400 μg	2.142	± 0.0100
Salmeterol/Fluticasone 50/500 μg	2.337	± 0.0100

Day 30: 5 minutes

Group	Value	95% CI
QMF149 150/320 μg	2.413	± 0.0142
QMF149 150/160 μg	2.406	± 0.0144
MF 800 μg	2.224	± 0.0145
MF 400 μg	2.174	± 0.0145
Salmeterol/Fluticasone 50/500 μg	2.360	± 0.0142

Day 30: 30 minutes

Group	Value	95% CI
QMF149 150/320 μg	2.432	± 0.0143
QMF149 150/160 μg	2.426	± 0.0145
MF 800 μg	2.238	± 0.0146
MF 400 μg	2.174	± 0.0146
Salmeterol/Fluticasone 50/500 μg	2.389	± 0.0143

Day 30: 1 hour

Group	Value	95% CI
QMF149 150/320 μg	2.448	± 0.0145
QMF149 150/160 μg	2.440	± 0.0146
MF 800 μg	2.257	± 0.0147
MF 400 μg	2.183	± 0.0148
Salmeterol/Fluticasone 50/500 μg	2.411	± 0.0144

Day 86:5 minutes

Group	Value	95% CI
QMF149 150/320 μg	2.411	± 0.0150
QMF149 150/160 μg	2.409	± 0.0150
MF 800 μg	2.248	± 0.0150
MF 400 μg	2.178	± 0.0153
Salmeterol/Fluticasone 50/500 μg	2.356	± 0.0148

Trough Forced Vital Capacity (FVC) Secondary · Up to Week 52 (Day 365)

FVC is the total amount of air exhaled during the FEV test. Trough FVC is defined as average of the two FVC measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. It was assessed by performing spirometric assessment.

Day 2

Group	Value	95% CI
QMF149 150/320 μg	3.342	± 0.0173
QMF149 150/160 μg	3.342	± 0.0174
MF 800 μg	3.256	± 0.0177
MF 400 μg	3.203	± 0.0173
Salmeterol/Fluticasone 50/500 μg	3.344	± 0.0176

Day 184

Group	Value	95% CI
QMF149 150/320 μg	3.372	± 0.0179
QMF149 150/160 μg	3.387	± 0.0180
MF 800 μg	3.322	± 0.0183
MF 400 μg	3.246	± 0.0182
Salmeterol/Fluticasone 50/500 μg	3.355	± 0.0180

Day 365

Group	Value	95% CI
QMF149 150/320 μg	3.394	± 0.0182
QMF149 150/160 μg	3.364	± 0.0181
MF 800 μg	3.319	± 0.0184
MF 400 μg	3.218	± 0.0183
Salmeterol/Fluticasone 50/500 μg	3.358	± 0.0182

Trough Forced Expiratory Flow (FEF)Between 25% and 75% of FVC (FEF25-75) Secondary · Up to Week 52 (Day 365)

FEF is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. Trough FEF25-75% is defined as average of the two FEF25-75% measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. It was assessed by performing spirometric assessment.

Day 2

Group	Value	95% CI
QMF149 150/320 μg	1.644	± 0.0186
QMF149 150/160 μg	1.617	± 0.0187
MF 800 μg	1.455	± 0.0191
MF 400 μg	1.406	± 0.0186
Salmeterol/Fluticasone 50/500 μg	1.662	± 0.0189

Day 184

Group	Value	95% CI
QMF149 150/320 μg	1.775	± 0.0249
QMF149 150/160 μg	1.738	± 0.0250
MF 800 μg	1.546	± 0.0253
MF 400 μg	1.473	± 0.0254
Salmeterol/Fluticasone 50/500 μg	1.692	± 0.0250

Day 365

Group	Value	95% CI
QMF149 150/320 μg	1.745	± 0.0259
QMF149 150/160 μg	1.686	± 0.0257
MF 800 μg	1.530	± 0.0261
MF 400 μg	1.440	± 0.0261
Salmeterol/Fluticasone 50/500 μg	1.692	± 0.0258

Change From Baseline in Morning and Evening Peak Expiratory Flow Rate (PEF) Over 26 and 52 Weeks of Treatment Secondary · Up to Weeks 26 and 52

PEF is a person's maximum speed of expiration. All the participants were instructed to record PEF twice daily using a mini Peak Flow Meter device, once in the morning (before taking the morning dose) and once approximately 12 h later in the evening (before taking the evening dose). At each timepoint, the participant was instructed to perform 3 consecutive manoeuvres within 10 minutes. These PEF values were captured in the e-PEF/diary. The best of 3 values were used.

Week 26: Mean morning PEF

Group	Value	95% CI
QMF149 150/320 μg	42.4	± 2.15
QMF149 150/160 μg	38.1	± 2.15
MF 800 μg	12.8	± 2.13
MF 400 μg	5.9	± 2.14
Salmeterol/Fluticasone 50/500 μg	29.1	± 2.14

Week 26:Mean evening PEF

Group	Value	95% CI
QMF149 150/320 μg	32.5	± 2.05
QMF149 150/160 μg	30.4	± 2.04
MF 800 μg	7.7	± 2.04
MF 400 μg	0.0	± 2.05
Salmeterol/Fluticasone 50/500 μg	23.9	± 2.04

Week 52:Mean morning PEF

Group	Value	95% CI
QMF149 150/320 μg	42.1	± 2.24
QMF149 150/160 μg	36.9	± 2.22
MF 800 μg	13.4	± 2.21
MF 400 μg	6.7	± 2.22
Salmeterol/Fluticasone 50/500 μg	28.3	± 2.22

Week 52:Mean evening PEF

Group	Value	95% CI
QMF149 150/320 μg	31.2	± 2.14
QMF149 150/160 μg	28.7	± 2.13
MF 800 μg	7.4	± 2.13
MF 400 μg	-0.3	± 2.14
Salmeterol/Fluticasone 50/500 μg	22.1	± 2.13

Percentage of Participants Achieving the Minimal Important Difference (MID) ACQ ≥ 0.5 at Weeks 26 and 52 Secondary · Weeks 26 (Day 183) and 52 (Day 364)

Change from baseline in ACQ-7 scores of ≤ 0.5 was defined as minimal clinically important difference and were considered clinically meaningful. The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway calibre (FEV1 % predicted). All 7 questions of the ACQ-7 were equally weighted. Items 1-5 were scored along a 7-point response scale, where 0 = totally controlled and 6 = severely uncontrolled. Item 6 is scored between 0 = no rescue medication and 6 = More than 16 puffs/inhalations most days. The 7th item was scored

Day 183

Group	Value	95% CI
QMF149 150/320 μg	76.4
QMF149 150/160 μg	76.2
MF 800 μg	72.3
MF 400 μg	66.9
Salmeterol/Fluticasone 50/500 μg	75.9

Day 364

Group	Value	95% CI
QMF149 150/320 μg	77.7
QMF149 150/160 μg	82.1
MF 800 μg	73.6
MF 400 μg	69.2
Salmeterol/Fluticasone 50/500 μg	77.3

Change From Baseline in Percentage of Asthma Symptoms Free Days Secondary · Up to Week 52

All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. Asthma symptoms free days are days with no daytime symptoms, no night-time awakenings and no symptoms on awakening. The daytime asthma symptom score was based on the daily e-diary recordings by participants with respect to shortness of breath, wheeze, cough, chest tightness, and impact on

Group	Value	95% CI
QMF149 150/320 μg	28.3	± 1.72
QMF149 150/160 μg	28.4	± 1.72
MF 800 μg	22.5	± 1.72
MF 400 μg	19.3	± 1.72
Salmeterol/Fluticasone 50/500 μg	24.9	± 1.72

Change Form Baseline in Percentage of Days With no Daytime Symptoms Secondary · Up to Week 52

All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. For days with no daytime symptoms, all 5 evening questions must have a score = 0 with respect to shortness of breath, wheeze, cough, chest tightness and impact on usual daily activities due to symptoms, each with scores from 0 (no problems) to 4 (very severe problems).

Group	Value	95% CI
QMF149 150/320 μg	28.0	± 1.69
QMF149 150/160 μg	28.0	± 1.69
MF 800 μg	23.0	± 1.68
MF 400 μg	20.0	± 1.69
Salmeterol/Fluticasone 50/500 μg	24.8	± 1.68

Change From Baseline in Percentage of Nights With no Night-time Awakenings Secondary · Up to Week 52

All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. The question asked for nights with no night-time awakenings was "How did you sleep last night?" had to be answered with "I did not wake up because of any breathing problems" with scores from 0 (no problem)-4 (very severe problems).

Group	Value	95% CI
QMF149 150/320 μg	17.0	± 1.28
QMF149 150/160 μg	16.4	± 1.27
MF 800 μg	14.2	± 1.27
MF 400 μg	12.5	± 1.27
Salmeterol/Fluticasone 50/500 μg	16.1	± 1.27

Adverse events — posted to ClinicalTrials.gov

Time frame: Serious adverse events: From first dose up to 30 days post last dose (approximately 56 weeks) Other adverse events: From first dose up to 7 days post last dose (approximately 53 weeks). Reporting threshold: 2%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

QMF 150/320

Serious: 21/443 (5%)

Deaths: 0/443

QMF 150/160

Serious: 20/437 (5%)

Deaths: 0/437

MF 800

Serious: 21/440 (5%)

Deaths: 0/440

MF 400

Serious: 31/443 (7%)

Deaths: 1/443

S/F 50/500

Serious: 21/444 (5%)

Deaths: 0/444

Serious adverse events (109 terms)

Reaction	System	QMF 150/320	QMF 150/160	MF 800	MF 400	S/F 50/500
Asthma	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—	—
Peritonitis	Infections and infestations	—	—	—	—	—
Acute myocardial infarction	Cardiac disorders	—	—	—	—	—
Rib fracture	Injury, poisoning and procedural complications	—	—	—	—	—
Atrial fibrillation	Cardiac disorders	—	—	—	—	—
Coronary artery disease	Cardiac disorders	—	—	—	—	—
Vertigo	Ear and labyrinth disorders	—	—	—	—	—
Goitre	Endocrine disorders	—	—	—	—	—
Corneal deposits	Eye disorders	—	—	—	—	—
Optic ischaemic neuropathy	Eye disorders	—	—	—	—	—
Retinal detachment	Eye disorders	—	—	—	—	—
Abdominal hernia	Gastrointestinal disorders	—	—	—	—	—
Abdominal pain upper	Gastrointestinal disorders	—	—	—	—	—
Diverticulum intestinal	Gastrointestinal disorders	—	—	—	—	—
Diverticulum intestinal haemorrhagic	Gastrointestinal disorders	—	—	—	—	—
Gastric polyps	Gastrointestinal disorders	—	—	—	—	—
Gastric ulcer haemorrhage	Gastrointestinal disorders	—	—	—	—	—
Gastritis	Gastrointestinal disorders	—	—	—	—	—
Inguinal hernia	Gastrointestinal disorders	—	—	—	—	—
Irritable bowel syndrome	Gastrointestinal disorders	—	—	—	—	—
Large intestine polyp	Gastrointestinal disorders	—	—	—	—	—
Pancreatitis acute	Gastrointestinal disorders	—	—	—	—	—
Peptic ulcer	Gastrointestinal disorders	—	—	—	—	—
Cholecystitis acute	Hepatobiliary disorders	—	—	—	—	—

Other adverse events (19 terms — click to expand)

Reaction	System	QMF 150/320	QMF 150/160	MF 800	MF 400	S/F 50/500
Asthma	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—
Nasopharyngitis	Infections and infestations	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—
Bronchitis	Infections and infestations	—	—	—	—	—
Viral upper respiratory tract infection	Infections and infestations	—	—	—	—	—
Influenza	Infections and infestations	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—
Respiratory tract infection viral	Infections and infestations	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—
Pharyngitis	Infections and infestations	—	—	—	—	—
Upper respiratory tract infection bacterial	Infections and infestations	—	—	—	—	—
Hypertension	Vascular disorders	—	—	—	—	—
Viral infection	Infections and infestations	—	—	—	—	—
Oropharyngeal pain	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—
Rhinitis allergic	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—
Rhinitis	Infections and infestations	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—
Gastroenteritis	Infections and infestations	—	—	—	—	—

Most-reported serious reactions: Asthma, Pneumonia, Peritonitis, Acute myocardial infarction, Rib fracture, Atrial fibrillation, Coronary artery disease, Vertigo.

Data from ClinicalTrials.gov NCT02554786 adverse events section.

Sponsor's own description

The purpose of the trial is to evaluate the efficacy and safety of two different doses of QMF149 (QMF149 150/160 µg and QMF149 150/320 µg via Concept1) over two respective MF doses (MF 400 µg and MF 800 µg via Twisthaler® (total daily dose)) in poorly controlled asthmatic participants as determined by pulmonary function testing, and effects on asthma control

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study.
van Zyl-Smit RN, Krüll M, Gessner C, Gon Y, et al · · 2020 · cited 35× · PMID 32653075 · DOI 10.1016/s2213-2600(20)30178-8
Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis.
Oba Y, Anwer S, Maduke T, Patel T, et al · · 2022 · cited 11× · PMID 36472162 · DOI 10.1002/14651858.cd013799.pub2
A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma.
Brittain D, D'Andrea P, Gruen E, Hosoe M, et al · · 2022 · cited 7× · PMID 35072888 · DOI 10.1007/s12325-021-02025-w
Inhaled steroids with and without regular formoterol for asthma: serious adverse events.
Janjua S, Schmidt S, Ferrer M, Cates CJ. · · 2019 · cited 6× · PMID 31553802 · DOI 10.1002/14651858.cd006924.pub4
Addition of long-acting beta2 agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta-analysis.
Oba Y, Anwer S, Patel T, Maduke T, et al · · 2023 · cited 5× · PMID 37602534 · DOI 10.1002/14651858.cd013797.pub2
One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies.
Chapman K, van Zyl-Smit R, Maspero J, Kerstjens HAM, et al · · 2021 · cited 4× · PMID 34452934 · DOI 10.1136/bmjresp-2020-000819
Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler<sup>®</sup> Device in Patients with Asthma.
Bartels C, Jain M, Yu J, Tillmann HC, et al · · 2021 · cited 4× · PMID 34024035 · DOI 10.1007/s13318-021-00689-x
Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma.
van Zyl-Smit RN, Chapman KR, Kerstjens HAM, Gessner C, et al · · 2023 · cited 2× · PMID 36714049 · DOI 10.2147/jaa.s392975

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02554786 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 5 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02554786.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing